“Global Perspectives” #4/2018 out now

December 21, 2018|HAEi News|

Dear HAE friends, With this fourth and final issue of the HAEi magazine Global Perspectives, we send you our sincerest best wishes for a festive holiday season and a healthy 2019. In this issue of our magazine you will, [...]

Enlarged Phase 2 Trial on Track

December 14, 2018|HAEi News|

KalVista Pharmaceuticals, Inc. has provided an operational update and released financial results for the fiscal second quarter ended October 31, 2018. CEO Andrew Crockett says: “We are still on track with our robust Phase 2 study [...]

Oral formulation rapidly absorbed

November 16, 2018|HAEi News|

BioCryst Pharmaceuticals, Inc. presents data showing that an oral formulation of BCX7353 was rapidly absorbed and exhibited a long half-life, two important characteristics of desired new acute treatments for HAE attacks. In the trial, the pharmacokinetic (PK) and [...]

Health Canada authorizes TAKHZYRO

September 20, 2018|HAEi News|

Shire plc and Shire Pharma Canada ULC (Shire Canada) announces that following priority review, Health Canada has authorized TAKHZYRO (lanadelumab injection) for routine prevention of attacks of HAE in adolescents and adults (12 years of [...]

KalVista Reports First Quarter Results

September 14, 2018|HAEi News|

From the KalVista Pharmaceuticals, Inc. financial results for the fiscal first quarter ended July 31, 2018: “Our recent financings provide significant additional capital for late-stage development of KVD900, our oral plasma kallikrein inhibitor for potential [...]

BioCryst reports positive results in trial

September 6, 2018|HAEi News|

BioCryst Pharmaceuticals, Inc. announces the initial results from the ZENITH-1 trial showing that a single 750 mg oral dose of BCX7353 was well tolerated and superior to placebo (p<0.05) against the majority of efficacy endpoints [...]

Shire acquires plasma collection company

September 6, 2018|HAEi News|

Shire plc has acquired sanaplasma AG, a source plasma collection company headquartered in Switzerland. The acquisition is expected to increase Shire’s access to plasma in the longer term and add to its European plasma collection network, [...]


August 24, 2018|HAEi News|

Following priority review, the U.S. Food and Drug Administration (FDA) has approved TAKHZYRO (lanadelumab-flyo) injection, for prophylaxis to prevent attacks of HAE in patients 12 years of age and older. “TAKHZYRO provides the HAE community [...]

Load More Posts

Stay Tuned

Be the first to know what’s going on in the world of HAE

Upcoming events

Apr 1, 2019 - May 31, 2019
HAE Global Walk 2019

May 23, 2019 - May 26, 2019
11th C1-INH Deficiency Workshop

United States
Jun 15, 2019
HAE IN-MOTION 5K walk/run

Jun 19, 2019 - Jun 20, 2019
Scientific and Practical International HAE Conference

>> View full event calendar

Check out our latest newsletters

HAE related topics that might interest you

Global Access Program

Helping to change the lives of patients with hereditary angioedema (HAE) with a medication access program

Global Perspectives

Magazine with timely information on the issues, activities, and events that are relevant to the global HAE community

HAEi Connect Member database

Free, secure online membership database and communications platform for HAEi’s member organizations

Regional Patient Advocates

Constantly strive to improve the situation for HAE friends all over the world – no matter how they are organized

Stay tuned – sign up for our newsletter


Click here to sign up

HAE Global Conference 2018

This 4th HAE conference was record breaking: A total of 736 patients and care givers participated from no less than 57 countries

HAEi hosted websites

Hosting of your national website or help for you to create a new website – naturally all in your native language